207 related articles for article (PubMed ID: 17852772)
1. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
Coban E; Afacan B
Platelets; 2008 Mar; 19(2):111-4. PubMed ID: 17852772
[TBL] [Abstract][Full Text] [Related]
2. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
4. The effect of weight loss on the mean platelet volume in obese patients.
Coban E; Yilmaz A; Sari R
Platelets; 2007 May; 18(3):212-6. PubMed ID: 17497433
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
6. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
Burmeister JE; Miltersteiner DR; Campos BM
J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
Ballantyne CM; Davidson MH; Setze CM; Kelly MT
J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
[TBL] [Abstract][Full Text] [Related]
9. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
Kostapanos MS; Derdemezis CS; Filippatos TD; Milionis HJ; Kiortsis DN; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Jan; 578(2-3):249-52. PubMed ID: 17931620
[TBL] [Abstract][Full Text] [Related]
10. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Ogata N; Fujimori S; Oka Y; Kaneko K
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):321-4. PubMed ID: 20544514
[TBL] [Abstract][Full Text] [Related]
11. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
[TBL] [Abstract][Full Text] [Related]
12. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
[TBL] [Abstract][Full Text] [Related]
13. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
14. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Malmström RE; Ostergren J; Jørgensen L; Hjemdahl P;
J Intern Med; 2009 Nov; 266(5):457-66. PubMed ID: 19549094
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Gazi I; Kostara C; Bairaktari ET; Elisaf M
J Clin Pharmacol; 2006 Nov; 46(11):1337-43. PubMed ID: 17050799
[TBL] [Abstract][Full Text] [Related]
16. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia.
ter Avest E; Abbink EJ; de Graaf J; Tack CJ; Stalenhoef AF
Eur J Clin Invest; 2005 Sep; 35(9):558-64. PubMed ID: 16128862
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
Pirro M; Schillaci G; Mannarino MR; Savarese G; Vaudo G; Siepi D; Paltriccia R; Mannarino E
Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):436-41. PubMed ID: 17134956
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
19. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
20. Lifestyle modification decreases the mean platelet volume in prehypertensive patients.
Yazici M; Kaya A; Kaya Y; Albayrak S; Cinemre H; Ozhan H
Platelets; 2009 Feb; 20(1):58-63. PubMed ID: 19172523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]